Where is Genopsy located?

Genopsy is headquartered in Seoul, South Korea.

Is Genopsy a funded company?

Genopsy is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Genopsy rank among its competitors?

Genopsy ranks 89th amongst 103 active competitors, of which 34 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Lucida Medical, which secured $11.5M in Mar, 2026.

Who are the top competitors of Genopsy?

Genopsy's top competitors include Nanovery, Scholar Rock and SamanTree Medical. Among them, Lucida Medical secured the most recent funding round in March, 2026.

Genopsy - 2026 Company Profile, Funding & Competitors

Genopsy is a funded company based in Seoul (South Korea), founded in 2018. It operates as a Developer of a medical device for the detection of cancer. The company has 103 active competitors, including 34 funded and 9 that have exited. Its top competitors include companies like Nanovery, Scholar Rock and SamanTree Medical.

Company Details

Developer of a medical device for the detection of cancer. The company uses nanowire technology to develop a medical device for the early detection, prognosis, and companion diagnosis of cancer by analyzing body fluids.

Key Metrics

Founded Year

2018

Location

Seoul, South Korea

Stage

Funding Raised

Investors

Ascendo Ventures & 1 more

Ranked

89^th among 103 active competitors

Similar Companies

Nanovery & 103 more

View Genopsy's full profile

Genopsy is a funded company. Genopsy has 2 institutional investors.

View details of Genopsy's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Genopsy include Nanovery, Scholar Rock and SamanTree Medical. Here is the list of Top 10 competitors of Genopsy, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Nanovery 2018, London (United Kingdom), Seed	Developer of nanobots for diagnosing cancer	$7.32M	prostate-cancer-research.org.uk, Earlymarket ... & 10 others	63/100
2nd	Scholar Rock 2012, Cambridge (United States), Public	Developer of Antibody-based drugs for the treatment of primary myopathies	$103M	Fidelity Investments, Invus & 9 others	61/100
3rd	SamanTree Medical 2014, Lausanne (Switzerland), Series C	Developer of digital microscopy system for high-resolution imaging of tissue	$57.5M	Panakes Partners, European Investment Bank ... & 12 others	58/100
4th	Lucida Medical 2019, Cambridge (United Kingdom), Series A	Developer of MRI-based cancer screening technology using artificial intelligence (AI)	$11.5M	prostate-cancer-research.org.uk, XTX Markets ... & 19 others	58/100
5th	Adiposs 2018, Geneva (Switzerland), Series A	Developer of medical imaging equipment for the diagnosis of cachexia	$7.25M	Foundation Eclosion, Privilege Ventures & 7 others	51/100
6th	Sysmex 1968, Kobe (Japan), Public	Developer of diagnostic instruments, reagents, and related software	-	-	51/100
7th	Windtree Therapeutics 1992, Philadelphia (United States), Public	Developer of therapies for oncology and cardiovascular diseases with unmet needs	$45K	VMS Asset Management, Panacea Venture & 2 others	50/100
8th	Ferronova 2016, Salisbury (Australia), Series A	Provider of magnetic probe based device of treatment of multiple cancer	$17.5M	Uniseed, SAVCF & 6 others	50/100
9th	RAYDIAX 2021, Magdeburg (Germany), Series A	Developer of therapy-assist CT system for minimally invasive interventions	$8.4M	Bmp Ventures, HTGF & 4 others	50/100
10th	Perfint Healthcare 2005, Chennai (India), Series D	Developer of solutions for image-guided interventional procedures	$41.5M	Norwest, Chiratae Ventures & 7 others	49/100
89th	Genopsy 2018, Seoul (South Korea), Funding Raised	Developer of a medical device for the detection of cancer	-	Ascendo Ventures, Alpen Route	20/100